European Medicines Agency consulting on a draft guideline on pharmacovigilance for medicines used in children
The European Medicines Agency (EMEA) has launched a six-month consultation period on a draft guideline on the conduct of pharmacovigilance for medicines used by the paediatric population, children from birth to 18 years of age.
The European Medicines Agency (EMEA) has launched a six-month consultationperiod on a draft guideline on the conduct of pharmacovigilance formedicines used by the paediatric population, children from birth to 18 yearsof age. This is the first guideline to focus exclusively on the issues ofsafety of medicines in children. The EMEA is consulting not only onreporting of adverse drug reactions in children, but also on the possibleneed for studies designed to follow the long-term safety of medicines inchildren.
According to the European Commission, more than 50 percent of medicines usedto treat children are prescribed on an unlicensed or 'off-label' basisbecause they have not been adequately tested and/or formulated andauthorised for use in children.
Differences in age and the stage of growth and development during childhoodmean that children may experience adverse drug reactions that vary innature, type and severity from those seen in adults. The systems fordetecting adverse drug reactions in children may not be as effective as foradults. Children may be unable to communicate adverse events or may not beaware that they experience an adverse event. In addition to under-reportingof reactions, off-label use may increase the occurrence of adverse drugreactions. The guideline aims at strengthening the pharmacovigilance systemfor all medicines used in children, whether specifically authorised for suchuse or not.
The European Commission proposed new legislation in September 2004 that aimsto stimulate the research, development and authorisation of medicines totreat children. The proposed regulation also contains a number of provisionsfor pharmacovigilance and the EMEA draft guideline is preparatory work witha view to implementing the regulation once it comes into force.
The European Medicines Agency in particular welcomes comments on thisguideline from healthcare professionals looking after paediatric patients.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
